Ivabradine: New Drug For The Heart Patients Approved

.

Ivabradine: New Drug For The Heart Patients Approved

A new study carried out by a team of doctors has proved that Ivabradine drug can help reduce the deaths caused by heart failure to a great extent. It is estimated that heart failure affects 900,000 people in UK, causing 100,000 deaths a year. However, the results of this drug are estimated to decline the death rate by more than a third.

Professor Martin Cowie, Consultant Cardiologist at the Royal Brompton Hospital in London who led this study, carried out a clinical trial ‘Shift’ before effusing the life saving statements. The clinical trials carried out on the drug showed that it abates the possibilities of death from heart failure by 39% and thus cutting the rate of hospital admissions by 24%.

A case that was considered while clinical trials added to the success story of this drug. Anne Tanner, who was diagnosed with heart failure in 2007, was put on this drug as part of her medication. The treatment has changed her life completely. She states that she is able to perform all the activities that she was unable to carry out before the treatment.

The main causes that doctors analyze in case of heart failure are articulated to be heart attack, that weaken the heart and due to this the pumping system is also damaged. As a result, there is a less supply of blood and thus oxygen to the heart. This drug further, acts by slowing down the heart beat. This action in turn helps the heart to pump oxygenated blood more efficiently. This drug is already used to treat angina.

The European Medicine Regulator, after beholding the consequences of the drug has approved its use for patients dealing with heart failure. This drug will be launched at a price rate that will cost no more than £1.50 a day, thus costing less than £10 a week.


Latest News

Brent Oil Climbs to More Than $50 per Barrel
Amazon
Protestors Demanding Minimum Wage Gather at Oak Brook
Toyota Entering Strategic Investment Deal with Uber
HP Enterprise will Spin Off its Enterprise Services Business Merging it with Com
Patrick Soon-Shiong invests $70.5 million in Tribune
Ares Capital planning to acquire American Capital
Although Scientists say GMOs are Safe to Eat But it is Not Easy to Convince Ever
Central States Pension Fund has No New Recovery Plan Seeks Legislation to Protec
Does Fewer Opioid Prescriptions in the U.S Reflect a Curb in the Wave of Addicti
Japan’s Exports Drop further in April adding to a Gloomy Outlook